not tagged
not tagged
['lymsm', 'lymphoma', 'cll']
#eha2022 | othman al-sawaf, , provided updated efficacy and safety data on ven-obi in cll with all patients being off study treatment for 4 years. pfs remained significantly superior for venobi vs clb-obi (median-nr vs 36.4 mo) #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm